How does interleukin-1 activate cells?  by O'Neill, Luke A.J.
Kidney International, Vol. 41(1992), pp. 546—549
How does interleukin-1 activate cells?
LUKE A.J. O'NEILL
Biochemistry Department, Trinity College, Dublin 2, Ireland
Interleukin-l (IL-I) belongs to a family of cell activators
termed cytokines. These are proteins which mediate the acti-
vation, differentiation or maturation of cells involved in immune
and inflammatory responses [reviewed in 1]. The advent of
cytokines has allowed elaborate networks to be established
between a wide variety of cell types. This has greatly improved
our understanding of the molecular and cellular events which
occur during inflammation.
IL-i can perhaps be considered the prototypical cytokine. It
occurs in two forms, IL-la and IL-l/3, both with a molecular
weight of 17000 daltons. The major cellular source of IL-i is the
activated mononuclear phagocyte and its many activities, both
in vivo and in vitro indicate that it is a central mediator of
inflammation [2, 31. IL-i is the most potent and multifunctional
activator of cells so far described in cell biology. In vitro, IL-i
activates a large number of cell types. It will induce IL-2
production from lymphocytes. From connective tissue cells it
induces prostaglandin and metalloproteinase production, as
well as a range of other cytokines such as IL-6 and colony
stimulating factors. A similar response is induced in mesangial
and endothelial cells, where it also increases the expression of
leukocyte adhesion molecules; in hepatocytes IL-I increases
the expression of several acute phase proteins. These effects
provide an explanation for the many in vivo responses to IL-I,
which include induction of fever, slow wave sleep, enhanced
immune reactivity, neutrophilia and the acute phase response.
Its effects in joints, where IL-i induces resorption of cartilage
and bone and leukocyte accumulation, have lead to IL-i being
implicated as a key mediator in rheumatoid arthritis. Despite
these many activities being well documented, the molecular
basis for the many potent and varied effects of IL-i remains
unclear. Elucidating the events which occur once IL-i binds to
cells has been a controversial area and there is still no consen-
sus [4]. Determining these events remains a clear goal for our
overall understanding of how IL-I works.
IL-i receptors
There are at least two distinct plasma membrane receptors
for IL-i. The first to be described was the 80 kdal form, now
termed type I [51. This is the predominant form and occurs on
T lymphocytes, connective tissue cells, endothelial cells and
mesangial cells. It has been cloned and is a member of the
immunoglobulin superfamily. Its structure did not yield any
clues as to a possible post-receptor signalling mechanism. The
second form, type II, was originally described on the pre-B cell
line 70Z/3 [6], and has a molecular weight of 67 kdal. It is now
known to occur mainly on bone-marrow derived cells. IL-i
receptors are present in low numbers compared to other hor-
mone receptors (for example, T lymphocytes express only 1 to
2000 receptors per cell). In order to explain the dramatic
changes in cellular activity which occur in response to IL-I, a
major amplification in signal must occur following receptor
binding.
G protein activation by IL-i
G proteins are guanine nucleotide binding proteins which
couple receptors to effector systems such as adenylyl cyclase
and phospholipases [71. As many G proteins can be activated by
a single occupied receptor, they provide a primary means of
amplifying the response to a hormone. There is evidence for G
protein activation in response to IL-i [8—101. In the murine
thymoma line EL4.NOB-l, I have shown that IL-I activates a
G protein within one minute of binding its receptor [8]. Simi-
larly, Chedid et a! have provided evidence for a G protein in the
signal for IL-i in synovial fibroblasts, YT cells and 70Z/3 cells
[9]. Much of the evidence is based on studies with pertussis
toxin, a bacterial toxin which causes whooping cough. Pertussis
toxin works by ADP-ribosylating the inhibitory G protein, Gi,
which inactivates it. If the toxin inhibits a biological response to
a hormone, Gi can then be implicated in the signal transduction
pathway for that hormone. I have shown that pertussis toxin
inhibits the induction of IL-2 from EL4 cells [8]. Chedid et al
demonstrated that the toxin inhibited a range of IL-I responses,
including induction of prostaglandin release from fibroblasts
and expression of IL-2 receptors on YT cells [9]. Dobson et al
showed that pertussis toxin inhibited increases in diacyiglycerol
induced by IL-i in EL4 cells [10]. Taken together, these reports
suggest an implicit role for Gi in IL-i signal transduction.
Recently, however, I have found evidence which indicates that
the inhibitory effect of pertussis toxin may be unrelated to
effects on Gi.
The B oligomer of pertussis toxin inhibits IL-I action
Pertussis toxin consists of six subunits [11]. The A subunit is
an ADP-ribosyltransferase and mediates the inactivation of Gi.
The remaining five subunits comprise the B oligomer of the
toxin, which is important for toxin binding. Figure 1 shows how
both the holotoxin and B oligomer potently inhibit the induction
of IL-2 by IL-i in EL4 cells. As the B oligomer is devoid of
ADP-ribosylating activity its inhibitory effect cannot involve
inactivation of a G protein. This implies that any modulatory
effect of the holotoxin on IL-I cannot be used as evidence to
implicate a G protein in IL-i action. The B oligomer was also
found to inhibit IL-i-induced prostaglandin release from human
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Fig. 1. Effect of pertussis toxin or B oligomer on IL-I -induced IL-2
production by EL4 cells. EL4 cells were preincubated for 4 hours at
37°C with holotoxin (•, 100 ng/ml), B oligomer (A, 100 ng/ml) or no
addition (0), washed and then incubated with increasing concentrations
of IL-I for 24 hours, after which supernatants were removed and
assayed for IL-2 on CTLL cells as described previously [81. Results are
expressed as U/mi IL-2 and are representative of two separate
experiments.
gingival fibroblasts (not shown), indicating that the effect of the
toxin was not restricted to lymphocytes. Interestingly, neither
toxin preparation affected phorbol ester-induced prostaglandin
production (not shown) suggesting that the effect of B oligomer
is somewhat specific for IL-i. The mechanism of action of the
B oligomer is unclear but it may prove a very interesting reagent
to use in probing IL-i signal transduction.
These toxin findings therefore suggest that the nature of the
IL-I activated G protein and its importance in IL-I action await
clarification.
IL-i, second messengers and protein kinases
Most cell activators lead to a change in the levels of specific
second messengers, such as cAMP or diacyiglycerol, within
minutes of binding receptor. This ultimately leads to a change in
the activity of a specific protein kinase which phosphorylates
discrete substrates ultimately leading to the cellular response.
cAMP and diacylglycerol are activators of protein kinase A and
C, respectively. There is disagreement as to whether IL-i can
change second messengers in cells. In agreement with some
laboratories I have been unable to detect increases in either
cAMP or diacyiglycerol [4]. However, other investigators have
detected changes in cAMP in lymphocytes and fibroblasts [12,
13]. There have also been reports on IL-i increasing diacylgiyc-
erol levels in cells, although the phospholipid source varies. In
T cells it is phosphatidyicholine, in macrophages, phosphatidyl-
inositol and in mesangial cells, phosphatildylethanolamine.
The significance of these changes to the final cellular re-
sponse to IL-i is ill-defined. Reports have appeared suggesting
both protein kinase A and protein kinase C involvement in IL-I
action 112, 13]. Protein kinase A is unlikely to be important for
IL-la, rn/n
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Fig. 2. Time course qf induction of NFKB by IL-i in EL4 cells. Cells (5
x l0 in I ml) were incubated times with IL-la (10 ng/ml) for the
indicated times, after which nuclear extracts were prepared as de-
scribed [18]. NFKB binding activity was measured using a standard
electrophoretic mobility assay technique [18]. In this method, 4 sg of
nuclear extract protein was incubated with [32P]-labelled DNA probes
containing the NFKB motif for 30 minutes at room temperature.
Protein-DNA complexes were then separated by electrophoresis and
identified by autoradiography. The arrows indicate the retarded bands
induced upon stimulation.
IL-I signalling however as other agents which activate this
kinase do not mimic IL-i. Protein kinase C activation by IL-i
was more likely since phorbol myristae acetate (PMA), which
activates protein kinase C, can induce many responses similar
to IL-I. However, studies on two proteins which are phosphor-
ylated in response to IL-i in fibroblasts, the small heat shock
protein hsp27 and the EGF receptor, strongly point to the lack
of involvement of protein kinase C in these phosphorylations
[14, 15]. It is likely that IL-i is activating a novel protein kinase,
distinct from protein kinase A or C in fibroblasts [151.
IL-i induces transcription factors
Although IL-i has been shown to increase the phosphoryla-
tion of proteins such as hsp27 and the EGF receptor, proteins
directly involved in transcription are likely to be more relevant
targets for phosphorylation, since the final cellular response to
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protein kinase C depleted cells, and staurosporine, a potent
inhibitor of protein kinase C, did not inhibit IL-i (Fig. 3). These
results strongly suggest that neither protein kinase A nor C are
important in IL-i action here. It is possible that a novel kinase,
similar to that described in fibroblasts is involved.
The mechanism of induction of NFKB by IL-i is currently
under investigation. A general model of activation by PMA has
been presented by Ghosh and Baltimore [161. This involves
phosphorylation of an inhibitory protein bound to the NFKB
complex, 1KB, which then dissociates, allowing the transcrip-
tion factor to translocate to the nucleus and bind to its cognate
sequence. Whether this occurs in response to IL-I awaits
determination.
Conclusions
-
Clearly the steps leading from IL-i binding to cells to a
change in gene expression are highly complex. Changes in G
protein, protein kinase and transcription factor activity are
likely to be involved. Determining the molecular details of these
events presents a major challenge and remains an essential
target for our understanding of this important molecule.
Reprint requests to Luke A.J. O'Neill, Ph.D., Biochemistry Depart-
ment, Trinity College, Dublin 2, ireland.
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Fig. 3. Effect of staurosporine on iL-I-induced NFKB in EL4 cells. EL4
cells were first preincubated with the indicated concentrations of
staurosporine, washed and then assessed for NFKB induction as de-
scribed in the legend to Figure 2.
IL-i is a change in gene expression. Changes in transcription
are mediated by DNA binding proteins termed transcription
factors, and several are known to be regulated by phosphory-
lation. Two are of particular interest with regard to IL-I: NFKB
and APi. Activation of both of these involves phosphorylation
[16, 17], and both are induced by IL-i [18, 191. APi and NFKB
sites have been detected in several IL-i responsive genes.
Genes containing API sites include IL-2 and collagenase genes
whilst those containing NFKB include IL-2 receptor and serum
amyloid A. The IL-2 gene contains sites for both factors
[reviewed in 201.
I have been studying the induction of NFKB by IL-i in EL4
cells. IL-i is a very strong inducer of this transcription factor in
these cells. Figure 2 shows how an increase in NFKB is
detectable from five minutes, peaks at 15 minutes and then
decreases. This transient response is very similar to the changes
in phosphorylation of the EGF receptor and suggests that
phosphorylation is involved. The increase was not mimicked by
forskolin, a protein kinase A activator, and while PMA induced
a change, the time course and pattern of induction was very
different (not shown). Also, there was still a response to IL-i in
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